Drug Type Small molecule drug |
Synonyms CBLC100 series, Curaxins |
Mechanism DNA intercalators, NF-κB inhibitors(Nuclear factor NF-kappa-B complex inhibitors), SSRP1 inhibitors(Structure specific recognition protein 1 inhibitors) + [3] |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Molecular FormulaC23H27ClN2O2 |
InChIKeyJURGRPIWKHUHSL-UHFFFAOYSA-N |
CAS Registry1197397-96-8 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Lung Cancer | Preclinical | US | 15 Apr 2010 | |
Lung Cancer | Preclinical | US | 15 Apr 2010 | |
Melanoma | Preclinical | US | 15 Apr 2010 | |
Melanoma | Preclinical | US | 15 Apr 2010 | |
Solid tumor | Discovery | US | - |